ALLR (Allarity Therapeutics) FCF Yield %: -79.77 (As of Jun. 26, 2026)


ALLR Allarity Therapeutics Inc ALLR
24 GF Score
Price $1.32
! 2 Warning Signs
View Full Analysis

What is Allarity Therapeutics FCF Yield %?

Allarity Therapeutics ALLR +2.73% 24 FCF Yield % is -79.77 as of Jun. 26, 2026. GuruFocus rates ALLR with a GF Score™ of 24/100. The stock has 2 warning signs investors should review. Among 1,418 Biotechnology companies, Allarity Therapeutics ranks worse than 88.58% on this metric.

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Allarity Therapeutics's Trailing 12-Month Free Cash Flow is $-16.69 Mil, and Market Cap is $20.92 Mil. Therefore, Allarity Therapeutics's FCF Yield % for today is -79.77%.

The historical rank and industry rank for Allarity Therapeutics's FCF Yield % or its related term are showing as below:

ALLR' s FCF Yield % Range Over the Past 10 Years
Min: -111.74   Med: -79.87   Max: -59.05
Current: -79.77


During the past 7 years, the highest FCF Yield % of Allarity Therapeutics was -59.05%. The lowest was -111.74%. And the median was -79.87%.

ALLR's FCF Yield % is ranked worse than
88.58% of 1418 companies
in the Biotechnology industry
Industry Median: -9.715 vs ALLR: -79.77

Allarity Therapeutics's FCF Margin % for the quarter that ended in Mar. 2026 was -18,228.00%.


Allarity Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Allarity Therapeutics FCF Yield % Related Terms


Allarity Therapeutics FCF Yield % Historical Data

* Premium members only.

The historical data trend for Allarity Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Allarity Therapeutics FCF Yield % Chart

Allarity Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Yield %
Get a 7-Day Free Trial 0.00 -238.75 -385.44 -206.57 -85.38

Allarity Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -67.37 -148.47 -53.58 -74.69 -105.71

ALLR vs OTLC, MRKR, SKYE: FCF Yield % Comparison

For the Biotechnology subindustry, Allarity Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Allarity Therapeutics FCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Allarity Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Allarity Therapeutics's FCF Yield % falls into.


ALLR
24GF Score
Allarity Therapeutics Inc ALLR
FCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Allarity Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Allarity Therapeutics's FCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-14.828 / 17.36748
=-85.38%

Allarity Therapeutics's annualized FCF Yield % for the quarter that ended in Mar. 2026 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-4.557 * 4 / 17.24271
=-105.71%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Yield % →
What does a FCF Yield % of -79.77 mean?
Allarity Therapeutics (ALLR) has a FCF Yield % of -79.77 as of Jun. 26, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Allarity Therapeutics and its competitors. According to the industry distribution chart, Allarity Therapeutics ranks #1256 out of 1418 companies in the Biotechnology industry, placing it in the top 88.6%.
Is Allarity Therapeutics' FCF Yield % too high?
Allarity Therapeutics' current FCF Yield % is -79.77. Based on the distribution chart, Allarity Therapeutics ranks #1256 out of 1418 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Allarity Therapeutics has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Allarity Therapeutics' FCF Yield % compare to OTLC and MRKR?
According to the Biotechnology industry distribution chart, Allarity Therapeutics ranks #1256 out of 1418 companies for FCF Yield %. This places Allarity Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Allarity Therapeutics and its competitors. Allarity Therapeutics's current FCF Yield % is -79.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allarity Therapeutics stock overvalued right now?
Allarity Therapeutics (ALLR) has a current FCF Yield % of -79.77. The current FCF Yield % is -79.77. Allarity Therapeutics' overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Allarity Therapeutics (ALLR), the current FCF Yield % is -79.77 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Allarity Therapeutics Business Description

Address 123 East Tarpon Avenue, Tarpon Springs, FL, USA, 34689
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.
24GF Score

Get the complete analysis for ALLR

FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.32
Price